Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
520 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 |
| NCT05465135 | The Effect of Dihydroartemisinin in PCOS | completed | Phase 4 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06420258 | Deeper Intubation Make Effects on Cervical Esophageal ESD | recruiting | Phase 4 | 40 | Fujian Provincial HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06368063 | The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer | recruiting | Phase 4 | 642 | Xi'an Jiaotong UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06311929 | Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma | recruiting | Phase 4 | 300 | Chen XiaopingOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03123406 | Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT(ACTIVE) | completed | Phase 4 | 750 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05661357 | Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression(HCCSC-C03) | unknown | Phase 4 | 51 | Zhongnan HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06339775 | Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation | recruiting | Phase 4 | 60 | Suping ZHANGOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05702905 | Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome | unknown | Phase 4 | 75 | Peking University First HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06329167 | Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery | unknown | Phase 4 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03629886 | Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study | completed | Phase 4 | 6,051 | GlaxoSmithKlineINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05411705 | Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury(Circular) | unknown | Phase 4 | 165 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06269445 | The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer | unknown | Phase 4 | 20 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06236022 | The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus(SDCMK) | recruiting | Phase 4 | 276 | Tongji HospitalOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06169410 | Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer | unknown | Phase 4 | 140 | Yang Jianjun, PhDOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer | terminated | Phase 4 | 68 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03151005 | The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | completed | Phase 4 | 70 | Xinqiao Hospital of ChongqingOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06118762 | Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | recruiting | Phase 4 | 30 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03608059 | ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center(ATG/PTCy) | completed | Phase 4 | 418 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04448873 | Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma | completed | Phase 4 | 30 | Children's Hospital of Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06026995 | Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells | unknown | Phase 4 | 174 | Chongqing University Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06001476 | Cold Snare Polypectomy for Small Bowel Polyps in Patients With Peutz-Jeghers Syndrome | unknown | Phase 4 | 40 | Shandong UniversityOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05603065 | Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)(TINES) | unknown | Phase 4 | 32 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05897749 | Clinical Study on the Effect of Brucea Javanica Oil Emulsion Injection on the Survival of Patients With Advanced Colorectal Cancer Who Failed to Receive Multi-line Treatment | unknown | Phase 4 | 60 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05861635 | The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression | unknown | Phase 4 | 42 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05844813 | Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma(NATARS) | enrolling by invitation | Phase 4 | 102 | Peking University International HospitalOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04508634 | Treating Obese PCOS Patients With LSG vs. Met | unknown | Phase 4 | 90 | Shanghai 10th People's HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809024 | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy | unknown | Phase 4 | 100 | Yongsheng WangOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05670561 | Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | unknown | Phase 4 | 60 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05718128 | Clinical Study of Endocardial Myocardial Biopsy | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05510544 | Plerixafor for Poorly Mobilized Lymphoma | unknown | Phase 4 | 140 | Peking UniversityOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05416073 | Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma(TACE-HAIC) | unknown | Phase 4 | 70 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials